Value
5.4/10data confidence 33%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Analyst target | 9.0 |
OABI · Why this verdict
Why OmniAb (OABI) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroRISK_OFF
TrendMatrix Research · core thesis
Engine thesis — one sentence
OmniAb is a speculative, cash-burning biotechnology platform whose losses are narrowing and whose recent earnings beats and revenue rebound support the story, but low business quality and binary industry risk keep it from earning a position.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Business quality is below average at 4.6, with cash burn and an operating margin of -49.5% flagged as value-trap signals. Bear case | Operating margin improves from -49.5% toward breakeven and free cash flow burn does not widen. | ↓Deteriorating |
| CounterThe Rule of 40 reading of 243 is rated elite and the current ratio is strong, so liquidity may fund the burn for a long time. | ||
Quarterly losses per share are narrowing, with the last two reported quarters beating estimates (-0.05 vs -0.13 and -0.06 vs -0.10). Earnings | EPS losses stay narrower than -0.10 per quarter and beats continue through the next four reports. | →Stable |
| CounterEarnings are lumpy and one quarter missed (-0.11 vs -0.09); the beats may reflect timing of milestone revenue rather than durable improvement. | ||
Quarterly revenue rebounded to $13.4M and $14.4M in the last two quarters from $2.2M in the September 2025 quarter, showing the revenue base can scale. Revenue quarters | Quarterly revenue holds above $8M on a trailing basis over the next 12 months. | →Stable |
| CounterRevenue swings widely (from $2.2M to $14.4M within two quarters), so the rebound may be milestone timing and not recurring. | ||
The price of $4.87 sits 50.1% below the analyst-derived take-profit of $7.31, but the industry is treated as binary and the position size recommendation is to avoid. Bull case | Price moves toward the $7.31 analyst target without breaching the $4.53 stop. | →Stable |
| CounterAnalyst targets in biotechnology are often stale or haircut, and implied volatility of 116% means the stop can be hit quickly. | ||
Momentum is constructive: rising on-balance volume, price above the 200-day average and institutions accumulating. Momentum breakdown | Price stays above its 200-day average and momentum stays at or above 5.5 over the next two quarters. | ↓Deteriorating |
| CounterChart signals are described as mixed with no clear pattern, and thin option open interest makes the technical read unreliable. | ||
Business quality is below average at 4.6, with cash burn and an operating margin of -49.5% flagged as value-trap signals.
↓DeterioratingBear case
- Expectation
- Operating margin improves from -49.5% toward breakeven and free cash flow burn does not widen.
CounterThe Rule of 40 reading of 243 is rated elite and the current ratio is strong, so liquidity may fund the burn for a long time.
Quarterly losses per share are narrowing, with the last two reported quarters beating estimates (-0.05 vs -0.13 and -0.06 vs -0.10).
→StableEarnings
- Expectation
- EPS losses stay narrower than -0.10 per quarter and beats continue through the next four reports.
CounterEarnings are lumpy and one quarter missed (-0.11 vs -0.09); the beats may reflect timing of milestone revenue rather than durable improvement.
Quarterly revenue rebounded to $13.4M and $14.4M in the last two quarters from $2.2M in the September 2025 quarter, showing the revenue base can scale.
→StableRevenue quarters
- Expectation
- Quarterly revenue holds above $8M on a trailing basis over the next 12 months.
CounterRevenue swings widely (from $2.2M to $14.4M within two quarters), so the rebound may be milestone timing and not recurring.
The price of $4.87 sits 50.1% below the analyst-derived take-profit of $7.31, but the industry is treated as binary and the position size recommendation is to avoid.
→StableBull case
- Expectation
- Price moves toward the $7.31 analyst target without breaching the $4.53 stop.
CounterAnalyst targets in biotechnology are often stale or haircut, and implied volatility of 116% means the stop can be hit quickly.
Momentum is constructive: rising on-balance volume, price above the 200-day average and institutions accumulating.
↓DeterioratingMomentum breakdown
- Expectation
- Price stays above its 200-day average and momentum stays at or above 5.5 over the next two quarters.
CounterChart signals are described as mixed with no clear pattern, and thin option open interest makes the technical read unreliable.
Per-dimension breakdown
Quality
4.6/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 0.0 |
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 8.2 |
| FCF quality | 0.0 |
| Moat | 7.2 |
| Rule of 40 | 9.5 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -1% of revenue
- ▸Rule of 40: 243 (elite)
Growth
5.0/10data confidence 50%Momentum
3.1/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.5 |
| MACD | 3.0 |
| OBV | 1.0 |
| MA position | 6.0 |
| Volume | 0.0 |
- ▸Volume distribution (falling OBV)
- ▸Above 200-day MA
Sentiment
7.6/10data confidence 100%| Component | Sub-score |
|---|---|
| Analyst rating | 7.6 |
| Price target | 9.9 |
| erm sentiment | 5.0 |
- ▸Light analyst coverage (6.0) — signal dampened
- ▸Analyst upside: 81%
Insider
6.7/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 5.0 |
| holder change | 10.0 |
| notable moves | 5.0 |
- ▸No net insider activity — $0 (0.000% of mkt cap)
- ▸Institutions accumulating
Peer rank
5.1/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 3.1 |
| quality rank | 3.3 |
| growth rank | 9.2 |
- ▸Industry growth leader
Technical
6.5/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 7.0 |
| support resistance | 5.6 |
| 52w position | 6.9 |
Risk (lower is worse)
5.7/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 6.9 |
| days to cover | 4.9 |
| volatility | 0.0 |
| put call | 10.0 |
| max pain risk | 3.0 |
| beta | 5.5 |
| debt equity | 9.7 |
- ▸Above max pain $2
Catalyst
6.4/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 5.6 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Earnings in 14 days
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (5)
- ASYMMETRY:3.9>=1.5
- INSIDER:OK
- NEWS_EVENTS:NONE_RECENT
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- MOMENTUM:3.1<4.5
Warning (2)
- 8K_CSUITE_CHANGE:5.02 (officer departure/appointment)
- EARNINGS_PROXIMITY:14d<=14d (soft)
Reward-to-Risk
3.87
Upside
+57.6%
Downside
14.9%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Sentiment at 7.6) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( MOMENTUM:3.1<4.5) reinforce the read. Current asymmetry R:R is 3.87 — supplementary context, not the trigger for this path.
The strongest dimensions are Sentiment at 7.6, Insider at 6.7, and Technical at 6.5; the weakest are Momentum at 3.1, Quality at 4.6, and Growth at 5.0. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of 3.87 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Narrowing Losses Earnings Beats
Trip ifEPS surprise stays below 0% for 2 consecutive quarters.
- P2Revenue Rebound Lumpy
Trip ifQuarterly revenue falls below $5M for 2 consecutive quarters.
- P3Cash Burn Low Quality
Trip ifOperating margin falls below -75% from current -49.5%.
- P4Analyst Upside Vs Binary Risk
Trip ifShare price drops to $4.53 or below, hitting the stop loss.
- P5Constructive Momentum Setup
Trip ifMomentum score falls below 4.5 from current 6.5.